Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS C-Gastric and Gastroesophageal Junction Carcinoma
NCT05251948Phase 2Terminated
- Sponsor
- Roche
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tiragolumab in Gastric carcinoma (GC) and gastroesophageal junction carcinoma (GEJ) (2 arms), sponsored by Roche. Primary endpoint: Objective Response Rate up to 42.1 months. Started Mar 2022; status: terminated.
02
Drugs
tiragolumab
03
Conditions
Gastric carcinoma (GC)gastroesophageal junction carcinoma (GEJ)
Beyond the preview
Go deeper on NCT05251948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251948.